Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3441-3460 of 3,900 trials

Usher Syndrome Type 1B: AAVB-081 Injection Study

We are testing a new subretinal injection for patients with Usher Syndrome Type 1B to see if it is safe and how it affects retinal health. The goal is to find a dose that balances safety and effectiveness.

Usher Syndrome Type 1B>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Immune Thrombocytopenia: Pirtobrutinib Study

We are investigating a new medication, pirtobrutinib, for adults with immune thrombocytopenia. The study aims to assess its safety and effectiveness compared to a placebo.

Immune Thrombocytopenia≤3 monthsSafety phase (I)Efficacy phase (II)11-15 visitsStandard MedicinesCost ReimbursementPartially RemoteHematology

Ischemic Stroke: Thrombolytic Therapy with rtPA

We are studying a new treatment for patients with acute ischemic stroke who are on blood thinners. The goal is to see if this therapy improves recovery compared to a placebo after reversing the blood thinner's effects.

Ischaemic Stroke3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Glaucoma: Oral Semaglutide Study

We are investigating whether oral semaglutide can safely improve retinal function in patients with open-angle glaucoma. This research may help find new ways to protect vision in those affected by this condition.

Glaucoma>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementEndocrinologyOphthalmology

Colorectal Cancer: Intravenous Iron Infusion Study

We are investigating whether intravenous iron can improve physical capacity and immune response in non-anemic patients with colorectal cancer. This study compares the effects of iron to a placebo to understand its potential benefits.

Iron Deficiency>2 yearsEfficacy phase (II)Investigational MedicinesGastroenterologyOncology

Allergic Rhinitis: New Immunotherapy Treatment

We are studying a new subcutaneous immunotherapy for patients with allergic rhinitis or rhinoconjunctivitis, with or without asthma. The goal is to evaluate its safety and effectiveness compared to a placebo.

Moderate to Severe Allergic Rhinitis with or without Asthma1-2 yearsEfficacy phase (II)Standard MedicinesAllergologyInternal Medicine

Myoclonic Astatic Epilepsy: Fenfluramine Safety Study

We are monitoring the long-term safety of Fenfluramine as an add-on therapy for patients with Myoclonic Astatic Epilepsy. This study aims to ensure the treatment is safe and effective for managing seizures.

Myoclonic-Astatic Epilepsy>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Early Alzheimer’s Disease: AD04 Treatment Study

We are testing a new treatment called AD04 to see if it can slow the progression of early Alzheimer’s disease. The study will also evaluate the safety of AD04 and its effects on quality of life.

Early Alzheimer's Disease>2 yearsEfficacy phase (II)Investigational MedicinesNeurologyPsychiatry

Diabetic Foot Syndrome: Stem Cell Treatment Study

We are investigating whether a new therapy using stem cells can help heal chronic wounds in people with diabetic foot syndrome. The study will compare this treatment to standard care to assess its safety and effectiveness.

Diabetic Foot Ulcer1-2 yearsEfficacy phase (II)Investigational MedicinesDiabetologyInternal Medicine

Metastatic Colorectal Cancer: Cetuximab Treatment Study

We are exploring a new treatment approach using cetuximab for patients with specific genetic markers in metastatic colorectal cancer. The study aims to understand its effectiveness, safety, and impact on quality of life.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Colonoscopy Prep: Comparing Plenvu® and Picoprep®

We are studying how well Plenvu® works compared to Picoprep® for cleaning the bowel before a colonoscopy. The goal is to see which option is more effective and easier for patients to tolerate.

Healthy Participants for Colonoscopy Preparation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterology

Echinococcosis: Albendazole Study

We are examining how the medication Albendazole is processed in the body of patients with cystic and alveolar echinococcosis. This study aims to improve treatment strategies for these infections.

Human Echinococcosis>2 yearsSafety phase (I)Infectious Diseases

Breast MRI: Low-Dose Gadolinium Study

We are testing whether a lower dose of gadolinium in breast MRI can provide image quality similar to the standard dose. This may help reduce contrast exposure while maintaining diagnostic accuracy.

Breast Cancer1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineOncologyOtolaryngology

Turner Syndrome: Oral vs. Transdermal Estrogen

We are studying whether oral and transdermal estrogen treatments provide similar benefits for women with Turner Syndrome. This research may help tailor hormone therapy to individual needs.

Turner's Syndrome≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Alzheimer's Disease: NSC001 Medication Study

We are investigating the safety and tolerability of a new medication, NSC001, for people with mild to moderate Alzheimer's disease. This study will help us learn more about how the medication works in the body.

Alzheimer's Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesNeurology

Antibiotic Levels in Pregnant Women with Twins

We are studying how antibiotics are processed in mothers of twins and their newborns. This research may help improve treatment safety and effectiveness for both mothers and babies.

Pregnancy≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsInfectious Diseases

Hematopoietic Cell Transplantation: Comparing Conditioning Regimens

We are comparing two treatment methods for patients receiving stem cell transplants from matched donors. The goal is to see if one method improves recovery rates better than the other.

Hematological Malignancies>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Ulcerative Rectal Colitis: Tofacitinib Response Study

We are researching what factors may predict how well patients with ulcerative rectal colitis respond to Tofacitinib therapy. This could help improve treatment strategies for better patient care.

Ulcerative Colitis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Mycobacterium Avium Complex Lung Infections: Comparing Antibiotics

We are studying whether azithromycin is as effective as clarithromycin for treating lung infections caused by Mycobacterium avium complex. The trial also examines safety and side effects of both treatments.

Mycobacterium Avium Complex Infection>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Steroid Withdrawal in Systemic Lupus Erythematosus (SLE)

We are studying whether stopping glucocorticoids is as effective as continuing a low dose for patients with stable SLE. This research aims to understand the impact on disease activity and quality of life over three years.

Systemic Lupus Erythematosus>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineRheumatology